Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Cincinnati, Ohio

Phase 1 cancer trials in Cincinnati, OH

38 Phase 1 cancer studies are recruiting participants at sites in Cincinnati as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cincinnati at a glance

  • 38 studies are recruiting at a site in Cincinnati.
  • By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (22).
  • By sponsor: industry (30), university, hospital or other (7), government (1).
  • By research area: Lymphoma (17), Lung Cancer (9), Breast Cancer (3), Melanoma (3), Pancreatic Cancer (3), Prostate Cancer (3).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Cincinnati

Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Aminex Therapeutics, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT07287917 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Cincinnati

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06287775 · updated
  2. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT07491497 · updated
  3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    The Christ Hospital Physicians - Mt. Auburn
    Registry record
    NCT06303505 · updated
  4. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    DualityBio Inc.
    Registry record
    NCT05914116 · updated
  5. Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genprex, Inc.
    Study site
    Oncology_Hematology Care Clinical Trials, LLC
    Registry record
    NCT05703971 · updated
  6. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  7. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

    • Phase 1/2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Iovance Biotherapeutics, Inc.
    Study site
    University of Cincinnati
    Registry record
    NCT05361174 · updated
  8. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    The Christ Hospital
    Registry record
    NCT06040541 · updated
  9. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Christ Hospital Cancer Center
    Registry record
    NCT05379985 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Cincinnati

  1. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Oncology Hematology Care Incorporated
    Registry record
    NCT04221542 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT05519449 · updated
  3. Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Oncology Hematology Care Incorporated
    Registry record
    NCT07493512 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Cincinnati

  1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04851119 · updated
  2. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Georgiamune Inc
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT06425926 · updated
  3. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT03947385 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Cincinnati

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04726241 · updated
  2. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Cincinnati Children's Hospital
    Registry record
    NCT06173518 · updated
  3. A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

    • Phase 1/2
    • From 6 months, up to 30 years
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05533775 · updated
  4. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    • Phase 1
    • From 24 months, up to 18 years
    • All sexes
    Sponsor
    ITM Solucin GmbH
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT06441331 · updated
  5. A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Umoja Biopharma
    Study site
    University of Cincinnatti Medical Center
    Registry record
    NCT06528301 · updated
  6. CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

    • Phase 1/2
    • From 12 months, up to 21 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04870944 · updated
  7. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    University of Cincinnati (UC) Physicians Company, LLC
    Registry record
    NCT05826535 · updated
  8. A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Lomond Therapeutics Holdings, Inc.
    Study site
    University of Cincinnati
    Registry record
    NCT06708897 · updated
  9. A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT05131022 · updated
  10. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

    • Early Phase 1
    • Ages 1 to 21
    • All sexes
    Sponsor
    Nationwide Children's Hospital
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT06333899 · updated
  11. Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

    • Phase 1/2
    • Up to age 21
    • All sexes
    Sponsor
    St. Jude Children's Research Hospital
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04195347 · updated
  12. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    • Phase 1
    • Ages 13 and older
    • All sexes
    Sponsor
    Newave Pharmaceutical Inc
    Study sites
    Cincinnati Children's Hospital Medical Center · University of Cincinnati
    Registry record
    NCT04771572 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Cincinnati

  1. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Oncology Hematology Care Primary
    Registry record
    NCT04657068 · updated
  2. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06445062 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Ask about studies near Cincinnati

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call